SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models
British Journal of Haematology · 2026-11 · 209 (5) · 2024-2033
DOI: 10.1111/bjh.70785 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 24.09.2026. Verfasst von Luise Albuquerque-Simões und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Nerve Tissue Proteins, Intercellular Signaling Peptides and Proteins, Mesenchymal Stem Cells. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences, University of Groningen/University Medical Center Groningen (UG/UMCG), the Nether….
Abstract (Originalsprache)
Acute myeloid leukaemia (AML) is supported by leukaemic stem cells (LSCs), whose continued existence and growth are dependent upon signals derived from their bone marrow (BM) microenvironment. Although the highly conserved glycoprotein slit guidance ligand 2 (SLIT2), implicated in axon guidance, has been proposed to support normal haematopoietic stem cell (HSC) function, its role in AML pathogenesis remains poorly defined. Here, we show that SLIT2 is downregulated in mesenchymal stem cells (MSCs) from AML patients. Patients with higher‐than‐normal SLIT2 protein levels had better outcomes, independently of classical risk factors. Functionally, knocking down (KD) SLIT2 in MSCs caused a reprogramming of the microenvironment. Specifically, SLIT2 ‐KD in MSCs resulted in increased expression of LSC‐supporting genes including C‐X‐C motif chemokne ligand 12 ( CXCL12) and KIT proto‐oncogene, receptor tyrosine kinase ( KIT ), and co‐culture of primary AML cells on SLIT2 ‐KD stromal cells prevented myeloid differentiation. Conversely, the addition of recombinant SLIT2 had cytostatic effects on AML cells, resulting in reduced proliferation and reduced clonogenicity in all tested models. Furthermore, in human xenograft models, systemic administration of recombinant SLIT2 resulted in a decrease in leukaemic burden in BM and spleen, delayed disease progression and improved survival. Overall, these data demonstrate that SLIT2 may act as a tumour suppressor, while SLIT2 loss impairs myeloid terminal differentiation, suggesting that SLIT2 signalling could serve as a potential therapeutic axis in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
- Center for Cell-Based Therapy, University of São Paulo, Ribeirão Preto, Brazil.
- Hematology Division, LIM31, Faculty of Medicine, University of São Paulo, São Paulo, Brazil.
- Department of Hematology, Institute of Cancer of São Paulo, São Paulo, Brazil.
- Myeloid Leukaemia Genomics and Biology Group, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
- Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
ORCID-Profile: Luise Albuquerque-Simões, Diego A Pereira-Martins, Lúcio Henrique Sousa Pinheiro, Livia Bassani Lins de Miranda, Rita de Cássia Cavaglieri, Lynn Quek, Steffen Boettcher, Jan Jacob Schuringa, Eduardo Magalhães Rego
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Abel Tasman Talent Program (ATTP) of the Graduate School of Medical Sciences, University of Groningen/University Medical Center Groningen (UG/UMCG), the Nether…
Zitieren
APA
Albuquerque-Simões, L., Weinhäuser, I., Pereira-Martins, D. A., Rojas, C. A. O., Pinheiro, L. H. S., de Miranda, L. B. L., Bianco, T. M., Cavaglieri, R. C., do Nascimento, M. C., Quek, L., Boettcher, S., Schuringa, J. J., & Rego, E. M. (2026). SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models. British Journal of Haematology, 209(5), 2024-2033. https://doi.org/10.1111/bjh.70785
Vancouver
Albuquerque-Simões L, Weinhäuser I, Pereira-Martins DA, Rojas CAO, Pinheiro LHS, de Miranda LBL, et al. SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models. British Journal of Haematology. 2026;209(5):2024-2033. doi:10.1111/bjh.70785
BibTeX
@article{AlbuquerqueSimes2026,
author = {Albuquerque-Simões, Luise and Weinhäuser, Isabel and Pereira-Martins, Diego A and Rojas, César Alexander Ortiz and Pinheiro, Lúcio Henrique Sousa and de Miranda, Livia Bassani Lins and Bianco, Thiago Mantello and Cavaglieri, Rita de Cássia and do Nascimento, Mariane Cristina and Quek, Lynn and Boettcher, Steffen and Schuringa, Jan Jacob and Rego, Eduardo Magalhães},
title = {SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2024--2033},
doi = {10.1111/bjh.70785}
}
EUVIMED